Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.

Stanley L Cohan,Keith Edwards,Lindsay Lucas,Tiffany Gervasi-Follmar,Judy O'Connor,Jessica Siuta,Vineetha Kamath,Lore Garten,Chiayi Chen, James Thomas,Kyle Smoot,Kiren Kresa-Reahl,Kateri J Spinelli

Multiple sclerosis journal - experimental, translational and clinical（2019）

引用 4|浏览2

暂无评分

摘要

Teriflunomide therapy initiated without natalizumab washout resulted in a low rate of return of disease activity. Clinicians may consider this a worthwhile strategy when transitioning clinically stable patients off natalizumab to another therapy.ClinicalTrials.gov Identifier: NCT01970410.

查看译文

关键词

Relapsing multiple sclerosis,anti-JC virus antibodies,disease recurrence,natalizumab,switch strategy,teriflunomide

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要